Evidence map›Paper›PMID 25212693›Full record

Trial reportDiabetes & vascular disease research2014

The effect of liraglutide on endothelial function in patients with type 2 diabetes.

Debashis Nandy, Christopher Johnson, Rita Basu, Michael Joyner, Jason Brett, Claus Bo Svendsen, Ananda Basu

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Diabetes & vascular disease research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00620282. Cited by 22 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 4 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00620282 phase3completed

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A 12-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial With an Open-label Glimepiride Arm

Ran2008Enrolled49Registered outcomes14Posted comparisons33ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsGlimepiride, liraglutide, Placebo
PMID 23010561PMID 25504028other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. The effect of DPP-4-protected GLP-1 (7-36) on coronary microvascular function in obese adults.International journal of cardiology. Heart & vasculature · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Debashis NandyMayo Clinic, Rochester, MN, USA.
Christopher JohnsonMayo Clinic, Rochester, MN, USA.
Rita BasuMayo Clinic, Rochester, MN, USA.
Michael JoynerMayo Clinic, Rochester, MN, USA.
Jason BrettNovo Nordisk, Inc., Plainsboro, NJ, USA.
Claus Bo SvendsenNovo Nordisk A/S, Søborg, Denmark.
Ananda BasuMayo Clinic, Rochester, MN, USA basu.ananda@mayo.edu.
Mayo Clinic · USMayo Clinic in Florida · USNovo Nordisk (Denmark) · DKNovo Nordisk (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This single-centre, 12-week, double-blind, placebo-controlled trial assessed how the human glucagon-like-peptide 1 analogue liraglutide impacted endothelial function in adult patients (n = 49) with type 2 diabetes and no overt cardiovascular disease. Patients were randomized to liraglutide, placebo or glimepiride. At baseline and Week 12, venous occlusion plethysmography was used to measure forearm blood flow (FBF) in response to acetylcholine (ACh) and sodium nitroprusside (SNP) before and after (L)-N(G)-monomethyl arginine (L-NMMA) infusion. At Week 12, ACh-mediated FBF increased with liraglutide and decreased with placebo; however, the between-treatment difference was not significant (p = 0.055). Inhibition of ACh-mediated FBF after L-NMMA infusion increased with liraglutide and decreased with placebo; this between-treatment difference was also not significant (p = 0.149). No change in FBF was observed with SNP. Liraglutide did not significantly impact endothelium-dependent vasodilation after 12 weeks; however, additional investigations looking at the effect of liraglutide on endothelial function in alternative vasculature and during the postprandial period are warranted.

Indexed as

AcetylcholineAgedBlood GlucoseBlood PressureBody WeightC-PeptideDiabetes Mellitus, Type 2Endothelium, VascularFemaleGlucagonGlucagon-Like Peptide 1Glucose Clamp TechniqueHumansHypoglycemic AgentsInsulinLipidsAcetylcholineBlood GlucoseC-PeptideGlucagonGlucagon-Like Peptide 1Hypoglycemic AgentsInsulinLipidsLiraglutideNitroprussideendothelial functionGlucagon-like peptide-1liraglutide

Identifiers

PMID25212693
OpenAlexW2099092790

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.